The most commonly reported adverse events of grade @ or worse in the safety population were lymphopenia ( @ -LSB- @ % -RSB- in the cilengitide group vs @ -LSB- @ % -RSB- in the control group ) , thrombocytopenia ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) , neutropenia ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) , leucopenia ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) , and convulsion ( @ -LSB- @ % -RSB- vs @ -LSB- @ % -RSB- ) .